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Abstract 
Amdani S.M.; Du W.; Aggarwal S. 
Outcome of Pediatric Heart Transplantation in Blood Culture Positive Donors in the 
United States 
Clinical transplantation 
Abstract 
Active donor infection at time of organ procurement poses a potential infection risk and may 
increase post-transplant morbidity and mortality in recipients. Our hypothesis was that pediatric 
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heart transplant recipients from blood culture positive donors (BCPD) would have increased 
morbidity and mortality compared to non-blood culture positive donors (NBCPD). A 
retrospective analyses of pediatric heart transplant recipients using the Organ Procurement and 
Transplant Network (OPTN) between 1987 and 2015 were conducted. Recipient as well as donor 
data were analyzed. Propensity score matching with 1:2 ratios was performed for recipient 
variables. Post-transplant morbidity and mortality was compared for recipients of BCPD and 
NBCPD. Among 9,618 heart transplant recipients, 450 (4.7%) were from culture-positive donors. 
Recipients of BCPD had a longer duration of Status 1A listing; diagnosis of congenital heart 
disease or restrictive cardiomyopathy and required support (IV inotropes, Inhaled NO and 
LVAD) prior to transplant. Post-transplant survival between the two groups were not different. 
Propensity matched recipients had similar length of stay; stroke rate; need for dialysis; 
pacemaker implantation and treated rejection episodes in the first year post transplant.  Careful 
acceptance of BCPD may have the potential to increase availability of donor hearts in the 
pediatric population. 
Keywords: Blood culture positive donors; pediatric heart transplant; transplant outcomes; UNOS 
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Introduction  
Heart transplantation is routinely offered to children with end-stage heart failure due to 
cardiomyopathies or secondary to various congenital heart diseases (CHD). [1-4] In recent years, 
survival outcomes for CHD surgery have improved. [5-7] Hence, in addition to children there is 
now an increasing flux of adults with congenital heart disease requiring heart transplantation. [8, 
9]  
   Limited donor availability of hearts remains a challenge, for which measures to maximize the 
donor pool are warranted. One of the many ways to increase the availability of organs is by using 
high-risk donors or suboptimal organs. Pediatric studies using high risk donors, donors 
previously refused and donors with depressed ventricular function have been successful. [10-12]  
    Donor transmitted infections are known to occur in 0.2-1.7% of all transplant procedures. [13, 
14] Immunosuppressants following organ transplantation further lowers immunity [15-17], 
making the recipient more susceptible to overt clinical infection or reactivation of a latent 
infection. Such infections, in turn, are reported to increase post-transplant morbidity and 
mortality in heart transplant recipients. [18, 19] 
A recent multi-center study by Forest et al. [20] evaluated short and long term heart transplant 
outcomes in adults following heart transplantation from blood culture positive donors (BCPD) vs. 
non-blood culture positive donors (NBCPD). Recipients of BCPD had higher rates of co-
morbidities, but overall survival was no different at 1 year (86 vs. 87%, p =0.2585) and at 15 
years (34% vs. 36%, p =0.0929). There is paucity of data, however, on post-transplant outcomes 
of pediatric recipients receiving hearts from BCPD. In this study, we compared morbidity and 
mortality outcomes of pediatric patients who received hearts from BCPD vs. NBCPD.  
 
Methods 
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This was a retrospective analysis of data obtained from the United Network of Organ Sharing 
Database (UNOS) Standard Transplant Analysis and Research files. UNOS is the regulatory 
agency responsible for the oversight of all solid organ transplantation in the United States. 
UNOS data include donor and recipient characteristics and follow-up outcomes of all patients 
who have undergone solid organ transplantation. The study was determined to be exempt from 
review by the Institutional Review Board of the Children’s Hospital of Michigan and Wayne 
State University as all protected health information was de-identified.  
Study design and data collection 
     Pediatric patients ≤ 18 years of age, either gender, undergoing single organ (heart) 
transplantation in the United States from 1987-2015 were included for this study. Adult patients 
(>18 years); and multi-organ transplants were excluded. Moreover, outcome variables with 
<50% reported values were excluded from analysis. 
     Donor variables included for analysis were: age; gender; ethnicity; weight; body surface 
area (BSA); body mass index (BMI); ABO blood type; cause of death; Hepatitis B and Hepatitis 
C status; cytomegalovirus (CMV) status; tattoos; source of infection (pulmonary, urine, other); 
risk status for blood-borne transmission; history of drug abuse (cocaine, intravenous (IV) or 
other drug use); ischemic time; receipt of IV inotropes; previous cardiopulmonary resuscitation 
(CPR); and left ventricular ejection fraction. 
    Recipient variables included for analysis were: age; gender; ethnicity; weight; BSA; BMI; 
days listed as UNOS status 1A; primary transplant vs. re-transplant; primary cardiac diagnosis -
dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), hypertrophic 
cardiomyopathy (HCM), congenital heart disease, Heart re-transplant and Other); ABO blood 
type; patient status prior to transplant (out of hospital, in hospital, ICU); support prior to 
transplant (ventilator, ECMO, IABP, IV inotropes, Dialysis, Inhaled nitric oxide, Other); 
ventricular assist device (VAD) use prior to transplant; Panel Reactive Antibody (PRA); prior 
cardiac surgery; serum albumin; year of transplant; infection requiring IV drug therapy 2 weeks 
before transplant; and donor-recipient ABO match. 
     Our primary outcome was patient survival post-transplant. Our secondary outcomes were 
post-transplant hospital length of stay; events prior to hospital discharge (stroke, dialysis, 
pacemaker implantation); and treated rejection episodes in the first year post transplant.  
Statistical analysis 
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  Summary statistics are presented as median (interquartile range), mean ± standard deviation, or 
number (percent) as appropriate. Recipient and donor characteristics were compared across 
groups using the Chi-square or Fischer’s exact tests for categorical variables and the Student’s t-
test or Wilcoxon rank-sum test for continuous variables, as appropriate, depending upon variable 
distribution. Cochrane-Armitage test was utilized to evaluate trend of utilization of BCPD 
overtime.  
  SAS PSMATCH [21] procedure utilizing the optimal method of propensity score matching with 
1:2 ratios was performed to achieve unbiased estimation of treatment effect in an observational 
study.  Optimal method selects all matches simultaneously without replacement to minimize the 
total absolute difference in propensity score across all matches.   The variables used in the above 
procedure included gender; ethnicity (white vs. non-white); ventilator , ECMO, VAD and 
dialysis prior to transplant; underlying diagnosis (congenital heart disease vs. others); year of 
transplant (before 2010 vs. 2010 and after); days as status 1A (≤ 7 days, 8-30 days, > 30 days); 
and age (< 1 year, 1-10 years, 10-18 years).   The PSMATCH procedure resulted in 449 cases 
and 898 controls.  
  The characteristics and outcomes of the two study groups were compared using t-tests and chi-
square tests after the propensity score matching.  Kaplan-Meier survival curves along with log-
rank test were used to compare graft and overall survival of the two study groups.  The 
conventional p-value < 0.05 was used to determine statistical significance. All data analyses 
were performed using SAS version 9.4 (SAS Inc., Cary, NC). 
Results  
A total of 9618 pediatric heart transplants were performed during the study period and 450 
(4.7%) children received organ from BCPD. There was a progressive increase in utilization of 
BCPD for heart transplantation over the years (p <0.0001). (Figure 1)  
Demographic characteristics of BCPD and NBCPD were similar with respect to gender, weight, 
body mass index (BMI), ABO blood type and Hepatitis B and C status. BCPD were more likely 
to be older [11-18 years (29.9 vs. 23.8%, p=0.04)]; of African American or Hispanic ethnicity 
(23.8 vs. 19%; 21.3 vs. 17% respectively, p=0.001); have died from anoxia (19.1 vs. 13.9%, 
p<0.0001) or drug intoxication (3.6 vs. 1.2%, p <0.0001); and more likely to have tattoos (7.8 vs. 
5.3%, p=0.03) on their body. Moreover, they were more likely (4.4 vs. 2.4%, p= 0.01) to be a 
Donor characteristics 
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Public Health Service increased risk donor [donors which were deemed to be at higher risk for 
HIV prior to 2013 and HIV, HBV and HCV after 2013], and to have a source of infection.  
History of drug abuse, however, was no different between two groups. (Table 1) 
 
 
 
Recipients of BCPD were no different than NBCPD with respect to age, gender, weight, BMI 
and previous history of transplant. However, recipients of BCPD were listed for a longer 
duration as UNOS status 1 [34.6 (29.4-39.9) vs. 24.9 (23.8-26.1) days, p=0.0004); more 
frequently had a history of congenital heart disease (19.1 vs. 13.7%; p=0.0003) or restrictive 
cardiomyopathy (6.4 vs. 4.3%, p=0.0003); and were more likely to be on IV inotropic support 
(46.2 vs. 38.3%, p=0.0009) and inhaled nitric oxide (1.3 vs. 0.5%, p=0.02) prior to transplant. 
Also, recipients of BCPD were more likely to be on left ventricular assist device (LVAD) 
support (8.2 vs. 4.5, p=0.0009) prior to transplant. Moreover, recipients of BCPD were more 
likely to have received IV drug therapy for infection two weeks prior to transplant (25.3 vs. 
16.3%, p <0.0001). (Table 2) 
Recipient characteristics 
 There were no differences in median patient survival between unmatched recipients of BCPD 
and NBCPD (p=0.15). (Figure 2a) In the matched cohort, there was no difference in 1-month 
survival (94.1 vs. 95.1%, p=0.51) and 6-month survival (88.9 vs. 89.9%, p=0.63) post-transplant. 
Post-transplant outcomes of recipients from BCPD vs. NBCPD 
 Moreover, long-term patient survival between matched recipients was also no different (p=0.72).  
(Figure 2b) 
Propensity matched BCPD and NBCPD recipients had similar median hospital length of stay 
[27.2 (24.3-30.2) vs. 27.5 (25.3-29.7) days, p=0.90); stroke rates (3.2 vs. 2.4%; p=0.36), need for 
dialysis (7 vs. 6.9%, p=0.91) and pacemaker implantation (0.9 vs. 1.1, p=1) post-transplant. The 
numbers of treated rejection episodes in the first year post transplant were also no different 
between both groups (28.7 vs. 29.2%, p 0=88). (Table 3)  
 
Discussion 
   Most recent UNOS/OPTN estimates (2011-2014) reveal that median waiting times for 
pediatric patients listed for heart transplants ranged from 72-188 days (the longest for children 1-
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5 years of age). [22] During the same time, the number of pediatric patients who were 
successfully transplanted was around 61.4-74.5%  with the lowest number in infants. In view of 
the limited supply of donor hearts, there has been a quest to evaluate outcomes following heart 
transplantation from suboptimal donors.  
    In our study, blood culture positive donors were utilized for transplants in only a minority of 
patients (4.7%). Whether this was because of fewer BCPD in the United States or the fact that 
there was low utilization of such donors is not known. It has been shown that there is a risk of 
transmitting donor infections to the recipient via transplant and such infections can increase early 
and late morbidity and mortality. [13, 14, 23-27] Moreover, pediatric patients do not have as 
many co-morbidities (diabetes, hypertension and end stage renal disease) as adults and hence 
centers tend to wait for an “ideal” donor organ. [28, 29] Thus the donor pool is often limited for 
use by these patients.  
        Although ideally transplanting centers would like to have all information (clinical and 
microbiological) about the donor, time constraints in which such screening must be carried out 
make it less likely that transplanting centers would have all this information until after transplant. 
[30] In our study, we found characteristics of donors who were more likely to be blood culture 
positive (adolescent; of African American or Hispanic ethnicity;  death from drug intoxication; 
and have other focus of infection). These characteristics may be used by the recipient center as a 
screening tool to identify such donors.   
      As expected, recipients who received BCPD had higher acuity of illness at time of transplant 
(longer duration as UNOS status 1A; underlying cardiac diagnosis of congenital heart disease or 
restrictive cardiomyopathy; on IV inotropes, inhaled nitric oxide and VAD support pre-
transplant) and would have likely died on the waitlist as shown in other studies [31-35] if centers 
had not accepted a BCPD. Interestingly, recipients of BCPD were more likely to have received 
IV drug therapy for infection in the two weeks prior to transplant. These patients were probably 
more prone to infection because they were more likely to have been on ECMO or VAD support, 
both of which are known to be associated with an increased infection risk. [36-40].    
   The survival in both unmatched and propensity matched analyses was comparable between 
BCPD and non-BCPD groups. Morbidities and hospital length of stay was also similar. These 
results, given the higher acuity of the BCPD recipients, are encouraging. These findings are 
similar to the adult study evaluating outcomes of blood culture positive donors in kidney [41], 
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liver [42] and heart transplantation. [20] Selective use of PHS "increased risk" donors have been 
shown in other analysis to result in similar post-transplant survival. [10] Donors at high risk of 
positive blood culture or those with known positive blood culture likely comprise some of this 
"increased risk" pool for which post-transplant survival is not impacted and therefore if all else 
with the donor seems suitable for transplant (considering the candidate's risk profile) then donor 
should not be declined solely on the basis of positive blood culture or likely positive blood 
culture. 
      Certain measures can be taken to decrease transmission of donor-derived infections to the 
recipients. Such measures include: (a) surveillance cultures of the transplant recipient to detect 
any infection post-transplant. (b) depending on the organism isolated from the donor, post-
transplant antibiotics directed against the organism for appropriate duration. [43-46] The use of 
BCPD, along with active surveillance and judicious use of antibiotics in such recipients will 
allow an expansion of  the donor pool for pediatric heart transplantation recipients without 
increasing morbidity and mortality. 
 Study Limitations 
Our study is based on analysis of registry data, which often depends on accurate data input by the 
participating centers. Post-transplant outcomes such as early in hospital mortality, post-transplant 
sepsis, long term morbidity, and coronary allograft vasculopathy were not available and hence 
could not be analyzed. We limited the outcomes analysis to only those variables that had more 
than 50% reported rates, thus reducing but definitely not eliminating a type II error. We didn't 
have detailed information about the bacterial strains. This information is important as virulent 
bacterial infections may have worse post-transplant outcomes than community acquired bacteria. 
Also, there is a possibility that a portion of blood culture positive donors may include individuals 
who have cultures that are positive for common contaminants such as coagulase negative 
staphylococcus which may not increase post-transplant morbidity or mortality.  Finally, we didn't 
have information for blood culture positive donors that never got utilized for transplantation. 
Whether the BCPD who were accepted for transplantation differed in some systematic way from 
those that were not accepted is unknown, and certainly possible.  
 
Conclusions 
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In this study, we utilized the largest national transplant registry to assess the characteristics and 
outcomes of BCPD in the pediatric population. Recipients of such BCPD donors were more 
likely to have higher acuity of illness and a higher likelihood of dying while waiting for 
transplant. Even though recipients of BCPD were sicker, post-transplant morbidity and mortality 
was not inferior to recipients receiving NBCPD. These findings suggest that careful acceptance 
of BCPD may have the potential to increase the availability of donor hearts without increasing 
post-transplant morbidity and mortality in children with end-stage heart failure. 
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Table 1. Demographic and Clinical Characteristics of donors   
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 No. of Patients 
n= 9618 
n (%) 
BCPD 
n=450 
Mean [95% CI], or n (%) 
NBCPD 
n= 9168 
Mean [95% CI], or n (%) 
p value 
Age, y  
  0-≤1 
  1-10 
  11-18 
  >18 
 
8714 (90.6) 
 
83 (20.3) 
136 (33.4) 
122 (29.9) 
67 (16.4) 
 
1953 (23.5) 
2945 (35.5) 
1980 (23.8) 
1428 (17.2) 
 
 
0.04* 
 
Weight 9126 (94.9) 34.8 [32.4-37.2] 32.6 [32.1-33.1] 0.08 
Donor BMI 8563 (89) 19.6 [19.1-20] 19.1 [19-19.2] 0.06 
Gender 
  Male 
  Female 
 
9617 (99.9) 
 
250 (55.6) 
200 (44.4) 
 
5240 (57.2) 
3927 (42.8) 
 
0.53 
Ethnicity  
 Caucasian 
  African American 
  Hispanic 
  Other 
 
9433 (98.1) 
 
235 (53.3) 
105 (23.8) 
94 (21.3) 
7 (1.6) 
 
5622 (62.5) 
1704 (19) 
1530 (17) 
136 (1.5) 
 
0.001* 
 
ABO blood type  
  O 
 
9448 (98.2) 
 
286 (63.6) 
 
5421 (60.3) 
 
0.51 
Cause of death  
  Anoxia * 
  Trauma #  
  Cardiovascular 
  Drug intoxication 
  Other † 
 
9485 (98.6) 
 
86 (19.1) 
190 (42.2) 
30 (6.7) 
16 (3.6) 
128 (28.4) 
 
1254 (13.9) 
4039 (44.7) 
564 (6.2) 
105 (1.2) 
3073 (34) 
 
 
<0.0001* 
 
Hepatitis B positivity 9618 (100) 2 (0.44) 70 (0.76) 0.78 
Hepatitis C positivity 9618 (100) 2 (0.44) 7 (0.08) 0.06 
CMV positivity 9618 (100) 265 (58.9) 4635 (50.6) 0.0006* 
Donor Tattoos 9618 (100) 35 (7.8) 490 (5.3) 0.03* 
Donor source of infection 
  Pulmonary  
  Urine 
  Other 
 
9618 (100) 
 
292 (64.9) 
186 (41.3) 
47 (10.4) 
 
2142 (23.4) 
502 (5.5) 
302 (3.3) 
 
 
<0.0001* 
 
Donor at risk for blood-borne 
disease transmission £ 
9618 (100) 20 (4.4) 217 (2.4) 0.01* 
Source of infection 
  Pulmonary  
  Urine 
  Other 
 
9618 (100) 
 
292 (64.9) 
186 (41.3) 
47 (10.4) 
 
2142 (23.4) 
502 (5.5) 
302 (3.3) 
 
 
<0.0001* 
 
Donor history of drug abuse 
  Cocaine  
  IV drug use 
  Other Drug use  
 
9618 (100) 
 
4 (0.9) 
0 (0) 
28 (6.2) 
 
62 (0.7) 
11 (0.12) 
448 (4.9) 
 
0.55 
1 
0.22 
Ischemic time > 4 9618 (100) 186 (41.3) 3312 (36.1) 0.03* 
Vasoactive support at 9618 (100) 186 (41.3) 2446 (26.7) <0.0001* 
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procurement 
Previous CPR 9618 (100) 27 (6) 451 (4.9) 0.32 
Donor left ventricular ejection 
fraction 
5713 (59.4) 63.6 [62.5-64.6] 62.8 [62.5-63.1] 0.17 
* Drowning, Seizure, Asphyxiation # Gunshot wound, stab, Gunshot/stab wound, blunt injury, electrical † SIDS, Intracranial hemorrhage/stroke, 
Death from natural causes, None of the above. 
£ Refers to Public Health Service Increased risk donors which are donors deemed to be at higher risk for HIV prior to 2013 and HIV, HBV and 
HCV after 2013.  
 
 
 
 
 
 
 
 
 
 
Table 2. Demographic and Clinical Characteristics of recipients 
 
 No. of Patients 
n= 9618 
n (%) 
BCPD 
n=450 
Mean [95% CI], or n (%) 
NBCPD 
n= 9168 
Mean [95% CI], or n (%) 
p value 
Age at listing  
  0-≤1 
  1-5 
  6-10 
  11-18 
 
9618 (100) 
 
139 (30.9) 
65 (14.4) 
75 (16.7) 
171 (38) 
 
3244 (35.4) 
1235 (13.5) 
1291 (14) 
3398 (37.1) 
 
 
0.18 
Gender  
  Male 
  Female  
 
9618 (100) 
 
235 (52.2) 
215 (47.8) 
 
4916 (53.6) 
4252 (46.4) 
 
0.56 
Ethnicity 
  Caucasian 
  African American 
  Hispanic 
  Other 
 
 
9304 (96.7) 
 
264 (60.6) 
73 (16.7) 
82 (18.8) 
17 (3.9) 
 
5797 (65.4) 
1559 (17.6) 
1307 (14.7) 
205 (2.3) 
 
0.014* 
Weight, kg  9469 (98.5) 27.5 [25.4-29.5] 26.6 [26.1-27] 0.41 
BMI  
  Underweight 
  Normal 
  Overweight 
  Obese 
 
 
9618 (100) 
 
326 (72.4) 
84 (18.7) 
27 (6) 
13 (2.9) 
 
6674 (72.8) 
1884 (20.5) 
381 (4.2) 
229 (2.5) 
 
 
0.22 
Days as UNOS status 1 9523 (99) 34.6 [29.4-39.9] 24.9 [23.8-26.1] 0.0004* 
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Re-transplant  9618 (100) 20 (4.4) 538 (5.9) 0.25 
Cardiac Diagnosis 
  Restrictive CMP 
  CHD 
  Other 
 
9491 (98.7) 
 
29 (6.5) 
86 (19.1) 
335 (74.4) 
 
390 (4.3) 
1241 (13.7) 
7410 (82) 
 
0.0003* 
Patient status prior to transplant 
  Out of hospital 
  In hospital/Intensive Care 
 
9593 (99.7) 
 
160 (35.6) 
290 (64.4) 
 
3294 (36) 
5849 (64) 
 
 
0.88 
 
Source of infection 
  Pulmonary  
  Urine 
  Other 
 
9618 (100) 
 
292 (64.9) 
186 (41.3) 
47 (10.4) 
 
2142 (23.4) 
502 (5.5) 
302 (3.3) 
 
 
<0.0001* 
 
Life support prior to transplant 
  Ventilator  
  ECMO  
  IABP  
  IV Inotropes 
  Inhaled NO 
  Other mechanism of life support 
 
9615 (99.9) 
9618 (100) 
9618 (100) 
9618 (100) 
9618 (100) 
9618 (100) 
 
80 (17.8) 
31 (6.9) 
3 (0.7) 
208 (46.2) 
6 (1.3) 
6 (1.3) 
 
1702 (18.6) 
440 (4.8) 
25 (0.3) 
3511 (38.3) 
42 (0.5) 
215 (2.4) 
 
0.71 
0.06 
0.14 
0.0009* 
0.02* 
0.19 
LVAD prior to transplant 9615 (99.9) 37 (8.2) 416 (4.5) 0.0009* 
Albumin  ≤3.5 g/dl 5476 (56.9) 181 (51.9) 2480 (48.4) 0.22 
Dialysis between listing and transplant 9615 (99.9) 12 (2.7) 188 (2.1) 0.39 
Infection requiring IV Drug therapy two 
weeks before transplant 
9618 (100) 114 (25.3) 1491 (16.3) <0.0001* 
Donor –Recipient Blood type  
Incompatible 
 
9617 (99.9) 
 
11 (2.4) 
 
156 (1.7) 
 
0.31 
Donor- Recipient weight ratio 9036 (93.9) 1.36 [1.32-1.41] 1.38 [1.37-1.39] 0.49 
Total bilirubin 
>2 mg/dl 
 
7299 (75.9) 
 
59 (14.5) 
 
996 (14.5) 
 
1 
 
 
 
 
 
 
 
 
 
Table 3. Post-transplant outcomes in patients transplanted with blood culture positive vs. propensity matched non-
blood culture positive donors 
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List of Figures 
 
Figure 1 - Trend in utilization of blood culture positive donors overtime (p<0.0001) 
 
Figure 2 - Kaplan- Meier survival outcomes for patients transplanted with blood culture positive vs. negative donors 
(a) Unmatched Cohort 
(b) Propensity Matched Cohort 
 BCPD 
n=449 
Mean [95% CI], or n (%) 
NBCPD 
n= 898 
Mean [95% CI], or n (%) 
p value 
Hospital length of stay (days) 27.2 [24.3-30.2] 27.5 [25.3-29.7] 0.90 
Stroke 14 (3.2) 20 (2.4) 0.36 
Dialysis 31 (7) 59 (6.9) 0.91 
Pacemaker implantation 4 (0.9) 9 (1.1) 1 
Treated rejection episodes in first year 
post transplant  
86 (28.7) 195 (29.2) 0.88 
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